

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Clarence N. Ahlem, et al.
Application No. : 10/602,330
Filed : June 23, 2003
Docket No. : 202.2D2
5 Title : Pharmaceutical Compositions and Treatment Methods
Examiner : Barbara P. Badio
Group Art Unit : 1617
Customer No. : 26551
Confirmation No. : 9052

INTERVIEW SUMMARY

Commissioner for Patents
P.O. Box 1450
15 Alexandria, VA 22313-1450

Dear Sir,

Applicants submit this paper by electronic submission as required under 37 CFR
20 § 1.133(b) after an interview with Examiner Badio on February 6, 2008 and a phone call
discussion on February 29, 2008. On February 6, 2008, the undersigned and Dr. James
Frincke, a co-inventor, discussed the pending claims and the outstanding rejection under
35 USC § 112, first paragraph. Applicants discussed evidence of record in support of
patentability, e.g., as indicated in Applicants' evidence of record, concerns that Examiner
25 Badio had about the claimed subject matter and potential claim amendments. The
undersigned sent amended claims with proposed claim amendments to Examiner Badio
by facsimile and Examiner Badio commented on the proposed amendments.

Applicants greatly appreciate Examiner Badio's courtesy and willingness to
discuss the claims with Applicants and her consideration of potentially allowable subject
30 matter in this application.

Date: March 11, 2008

Hollis-Eden Pharmaceuticals, Inc.
35 4435 Eastgate Mall, Suite 400
San Diego, CA 92121

Respectfully submitted,

/Daryl D. Muenchau/

Daryl D. Muenchau,
Reg. No. 36,616
Phone: 858-320-2569